Abstract:Patients with type 2 diabetes mellitus (T2DM) exhibit hyperglycemia and hyperinsulinemia and increased risk of fracture at early stage, but they were found to have normal or even enhanced bone mineral density (BMD). This study was aimed to examine the molecular mechanisms governing changes in bone structure and integrity under both hyperglycemic and hyperinsulinemic conditions. Monocytes were isolated from the bone marrow of the C57BL/6 mice, induced to differentiate into osteoclasts by receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) and exposed to high glucose (33.6 mmol/L), high insulin (1 μmol/L), or a combination of high glucose/high insulin (33.6 mmol/L glucose and 1 μmol/L insulin). Cells cultured in α-MEM alone served as control. After four days of incubation, the cells were harvested and stained for tartrate resistant acid phosphatase (TRAP). Osteoclast-related genes including RANK, cathepsin K and TRAP were determined by using real-time PCR. The resorptive activity of osteoclasts was measured by using a pit formation assay. Osteoclasts that were derived from monocytes were of multinucleated nature and positive for TRAP, a characteristic marker of osteoclasts. Cell counting showed that the number of osteoclasts was much less in high glucose and high glucose/high insulin groups than in normal glucose and high insulin groups. The expression levels of RANK and cathepsin K were significantly decreased in high glucose, high insulin and high glucose/high insulin groups as compared with normal glucose group, and the TRAP activity was substantially inhibited in high glucose environment. The pit formation assay revealed that the resorptive activity of osteoclasts was obviously decreased in high glucose group and high glucose/high insulin group as compared with normal group. It was concluded that osteoclastogenesis is suppressed under hyperglycemic and hyperinsulinemic conditions, suggesting a disruption of the bone metabolism in diabetic patients.

The Role of Wnt Signaling in Diabetes-Induced Osteoporosis

Wnt Signaling:Essential Roles in Osteoblast Differentiation,bone Metabolism and Therapeutic Implications for Bone and Skeletal Disorders

Hyperglycemia Induces Endoplasmic Reticulum Stress-Dependent CHOP Expression in Osteoblasts

The Effect of Diabetes on the Bone Metabolism

Potential Metabolic Pathways Involved in Osteoporosis and Evaluation of Fracture Risk in Individuals with Diabetes

Hyperglycemia impairs osteoblast cell migration and chemotaxis due to a decrease in mitochondrial biogenesis

Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis.

Progress of Wnt Signaling Pathway in Osteoporosis

Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment

Bradykinin Receptors and EphB2/EphrinB2 Pathway in Response to High Glucose-Induced Osteoblast Dysfunction and Hyperglycemia-Induced Bone Deterioration in Mice

The complex pathophysiology of bone fragility in obesity and type 2 diabetes mellitus: therapeutic targets to promote osteogenesis

Focusing on Bone—new Means for the Management of Diabetes

A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment

Bone: Another potential target to treat, prevent and predict diabetes

Diabetes and Its Effect on Bone and Fracture Healing

Mtor Signaling Pathway in Bone Diseases Associated with Hyperglycemia

Bone metabolism in diabetes: a clinician's guide to understanding the bone–glucose interplay

Type 1 Diabetes and Osteoporosis: From Molecular Pathways to Bone Phenotype

The Inhibition of PINK1/Drp1-mediated Mitophagy by Hyperglycemia Leads to Impaired Osteoblastogenesis in Diabetes